Canagliflozin: Cui Bono?
- PMID: 29133603
- DOI: 10.1161/CIRCULATIONAHA.117.032198
Canagliflozin: Cui Bono?
Keywords: Editorials; diabetes mellitus, type 2; heart failure; primary prevention; secondary prevention.
Comment on
-
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133604 Free PMC article. Clinical Trial.
Similar articles
-
Pump, pipes, and filter: do SGLT2 inhibitors cover it all?Lancet. 2019 Jan 5;393(10166):3-5. doi: 10.1016/S0140-6736(18)32824-1. Epub 2018 Nov 10. Lancet. 2019. PMID: 30424891 No abstract available.
-
Diabetes: Further insights into SGLT2 inhibitors.Nat Rev Cardiol. 2018 Jan;15(1):2-3. doi: 10.1038/nrcardio.2017.198. Epub 2017 Nov 30. Nat Rev Cardiol. 2018. PMID: 29188808 No abstract available.
-
Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".Circulation. 2019 Jan 15;139(3):416-417. doi: 10.1161/CIRCULATIONAHA.118.037209. Circulation. 2019. PMID: 30640544 No abstract available.
-
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.Curr Med Res Opin. 2016 Aug;32(8):1375-85. doi: 10.1080/03007995.2016.1174841. Epub 2016 May 6. Curr Med Res Opin. 2016. PMID: 27046479 Review.
-
Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.Postgrad Med. 2017 Jan;129(1):159-168. doi: 10.1080/00325481.2017.1256747. Epub 2016 Nov 28. Postgrad Med. 2017. PMID: 27894216 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources